[{"id":"58d26922-dd62-4243-8588-89fbcbf5d940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152995","created_at":"2021-03-24T14:59:26.184Z","updated_at":"2025-02-25T12:26:08.615Z","phase":"Phase 2","brief_title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02152995","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • NRAS • HRAS • EGF","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61","tags":["HER-2 • KRAS • BRAF • NRAS • HRAS • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 01/25/2026","study_completion_date":" 01/25/2026","last_update_posted":"2025-02-24"},{"id":"d78d7b46-d2cc-485a-8c04-81f9d73189d4","acronym":"KEYNOTE-E28","url":"https://clinicaltrials.gov/study/NCT04429542","created_at":"2021-01-18T21:20:02.191Z","updated_at":"2025-02-25T16:10:23.024Z","phase":"Phase 1","brief_title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","source_id_and_acronym":"NCT04429542 - KEYNOTE-E28","lead_sponsor":"Bicara Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-27"},{"id":"5cdbdbf3-e8da-4789-91ba-999fa7089d8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454035","created_at":"2021-01-18T17:01:52.689Z","updated_at":"2024-07-02T16:35:22.023Z","phase":"Phase 1","brief_title":"Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors","source_id_and_acronym":"NCT03454035","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" KRAS • BRAF • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61","tags":["KRAS • BRAF • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ulixertinib (BVD-523)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/30/2018","start_date":" 01/30/2018","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 04/24/2026","study_completion_date":" 04/24/2026","last_update_posted":"2024-01-26"},{"id":"ccf0a3d0-2d12-4172-9a35-f6327f190184","acronym":"","url":"https://clinicaltrials.gov/study/NCT05254184","created_at":"2022-02-24T14:52:57.088Z","updated_at":"2024-07-02T16:35:22.368Z","phase":"Phase 1","brief_title":"KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC","source_id_and_acronym":"NCT05254184","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-01-24"},{"id":"6eb97f2c-ec9d-435c-8cbb-be3b4fce8c70","acronym":"","url":"https://clinicaltrials.gov/study/NCT03284502","created_at":"2021-01-18T16:13:34.748Z","updated_at":"2024-07-02T16:35:41.554Z","phase":"Phase 1","brief_title":"HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03284502","lead_sponsor":"Hanmi Pharmaceutical Company Limited","biomarkers":" KRAS • BRAF • NRAS • PI3K","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G13D • RAS mutation • BRAF fusion • KRAS G13 • NRAS G13","tags":["KRAS • BRAF • NRAS • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G13D • RAS mutation • BRAF fusion • KRAS G13 • NRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Cotellic (cobimetinib) • belvarafenib (RG6185)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-08-01"},{"id":"0571b3b6-6285-4835-ab7e-a7fe6fcc54ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02942095","created_at":"2021-01-18T14:26:45.911Z","updated_at":"2025-02-25T14:50:19.404Z","phase":"Phase 1","brief_title":"Study of Ixazomib and Erlotinib in Solid Tumors","source_id_and_acronym":"NCT02942095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR T790M • KRAS G12 • EGFR positive • KRAS G13 • EGFR negative","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR T790M • KRAS G12 • EGFR positive • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Ninlaro (ixazomib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/06/2017","start_date":" 03/06/2017","primary_txt":" Primary completion: 12/07/2022","primary_completion_date":" 12/07/2022","study_txt":" Completion: 12/07/2022","study_completion_date":" 12/07/2022","last_update_posted":"2023-04-18"},{"id":"b2c74ab4-c1bb-4e58-a7dd-cb64d3bac04a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05651269","created_at":"2022-12-15T15:58:36.795Z","updated_at":"2024-07-02T16:35:59.048Z","phase":"Phase 2","brief_title":"Milciclib in Combination With Gemcitabine in Advanced NSCLC","source_id_and_acronym":"NCT05651269","lead_sponsor":"Tiziana Life Sciences LTD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • milciclib (TZLS-201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-12-15"}]